Yasmin/Yaz Lawsuits Look to Consolidate Claims

After the recent reports indicating possible problems with Yasmin and Yaz side effects, lawsuits were filed in several states against Bayer Pharmaceuticals Corporation and other Bayer related companies. These suits allege that Bayer did not provide adequate warnings advising that Yaz and Yasmin side effects may increase the risk of serious health complications, including heart attacks, strokes, gallbladder disease, deep vein thrombosis (DVT), pulmonary embolism (PE).

In the wake of these suits being filed, three main firms responsible for managing the majority of these lawsuits (23 of the 32 filed cases around the country) have filed a joint motion asking that the Yasmin and Yaz product liability litigation be consolidated. This motion would condense the suits and transfer them to Chief Judge James G. Carr of the United States District Court for the Northern District of Ohio.

Lawsuits were filed against Bayer after a series of reports were released linking Yasmin/Yaz to several deaths nationwide. Some of these cases were fatal; complications included such serious effects as stroke and heart attacks. The complications were caused by different factors, but one of the most notable interactions between the contraceptive and women’s bodies was the presence of high levels of potassium. These raised levels are potentially dangerous for women with preexisting conditions such as diabetes, obesity, chronic high blood pressure, renal (kidney) conditions, history of stoke, or deep vein thrombosis. Often times, women were not warned of the possibility of these very serious side effects.

In fact, Bayer has been in trouble in the past for misleading advertisements. In 2003, the Food and Drug Administration (FDA) issued a warning to Berlex Laboratories, an integrated part of the Bayer Pharmaceuticals Corporation, advising them to cease the use of an advertisement for Yasmin. The FDA claimed that the advertisement was misleading, making Yasmin seem as if the side effects were significantly reduced and minimized the warnings of serious health complications due to side effects, especially when the FDA had empirical evidence indicating that drospirenone (one of the chemicals in Yasmin/Yaz) presented added clinical risks. Additionally, the FDA advised Berlex that the advertisement made Yasmin seem superior to other contraceptives currently available.

Despite the removal of the ad and an expensive campaign to correct their mistake, Yasmin is still the top selling oral contraceptive in the nation; in 2008, Yaz accounted for 17.7% of the birth control market with sales of $ 616 million and Yasmin had an additional 11% of the market with $ 382 million in sales. Both of these drugs now carry the FDA’s strongest warning label, though both of them still present a serious risk.

Individuals seeking information regarding Yasmin/Yaz are encouraged to visit LegalView.com for access to a wealth of resources, including developing a Yasmin/Yaz lawsuit and contacting a Yasmin/Yaz lawfirm.

Leave a Reply

Your email address will not be published. Required fields are marked *